Long term sale of imatinib in india Gleevec price 18710176959

Trade name: Gleevec hotline Ms. Zhang Common name: Imatinib mesylate
English name:
[Main ingredient] Imatinib mesylate.
【Properties】This product is a capsule, the content is white to off-white powder.
[Indications] It is used to treat patients with malignant gastrointestinal stromal tumors that cannot be surgically resected or have metastasized in patients with chronic myelogenous leukemia () in blast phase, accelerated phase or chronic phase after failure of interferon therapy.
[Usage and Dosage] For patients in the blast phase and accelerated phase of chronic myelogenous leukemia, the recommended dose of imatinib mesylate is /day. For patients in the chronic phase who have failed interferon therapy, as well as those who cannot be surgically resected or have metastasis For patients with malignant gastrointestinal stromal tumors, the recommended dose is/day, which should be taken orally once a day. It should be taken with a meal and a large glass of water. As long as it is effective, it should be continued. If the blood picture permits and there are no serious adverse drug reactions, the dose may be considered to be increased from /day to /day, or from /day to /day (taken in divided doses) under the following circumstances: disease progression, no response after at least 3 months of treatment A satisfactory hematological response can be obtained, and the hematological response that has been achieved disappears again. The dose must be adjusted in the following circumstances: If serious non-hematological adverse reactions (such as severe water retention) occur during treatment, the drug should be discontinued until the adverse reactions disappear, and then the dose will be adjusted according to the severity of the adverse reactions. Dosage adjustment in case of severe liver toxicity: If the increase in bilirubin exceeds 3 times the upper limit of the normal range or the increase in transaminases exceeds the upper limit of the normal range, the drug should be discontinued until the above indicators drop to . or less than . times the upper limit of the normal range respectively. . Dose adjustment in the event of neutropenia or thrombocytopenia: Acceleration or blast phase: If severe neutropenia and thrombocytopenia occur (neutrophils/and/or platelets/, it is recommended that the dose be reduced to /day. If If the blood cells continue to decrease for weeks, the dose should be further reduced to 3/day. If the blood cells continue to decrease for weeks, it is advisable to stop the drug until neutrophils (rr) and platelets (rr)/ are used. The dose is 3/day when used again. - Patients in the chronic phase after interferon treatment failure: it is advisable to stop taking the drug when neutrophils (rr) and/or platelets are present, and resume medication only when neutrophils (rr) and platelets (rr) are present. The dose is /day , if the neutrophils or platelets are reduced to the above values again, the dose is reduced to 3/day when the drug is resumed. Children and Adolescents: There is no safety and effectiveness of imatinib mesylate treatment in patients under the age of 16 Clinical data. Dosage in patients with liver failure: The plasma concentration of imatinib mesylate may increase in patients with liver dysfunction, so these patients should be cautious when using this drug. Currently, there is no use of imatinib mesylate in patients with liver dysfunction. The clinical data of imatinib cannot make recommendations for dose adjustment. Dosage in renal failure and elderly patients: Creatinine clearance is known to decrease with age, and age has an impact on the pharmacokinetics of imatinib mesylate. There is no obvious impact on the study. Since no clinical trials have been conducted in patients with renal impairment, no dosage adjustment recommendations can be made.
[Adverse Reactions] Most patients will experience some adverse effects while taking imatinib mesylate. reactions, but the vast majority are mild to moderate. Considering that the disease itself also produces symptoms, it is often difficult to clarify their causal relationship. During clinical trials, those who discontinued medication due to drug-related adverse reactions were treated with interferon Only 10% of patients in the chronic phase of chronic myeloid failure failed, approximately 1% in the accelerated phase, and 1% in the blastic phase of chronic myeloidosis. The most common adverse events related to drug treatment are mild nausea (-), vomiting, diarrhea, myalgia and muscle spasm. Adverse events are easy to handle. Edema and water retention were reported in all studies, with incidence rates of - and, respectively, of which severe cases were and -. Most patients' edema manifested as periorbital and lower extremity edema, and pleural effusion, pleural effusion, Ascites, pulmonary edema and rapid weight gain, the drug is usually suspended at this time, diuretics or certain supportive treatments are given. Some patients are in serious condition and even life-threatening. There are cases of patients with chronic myeloid blasts who were complicated by pleural effusion, congestive heart failure and Death due to complex clinical conditions of renal failure. The incidence of these adverse reactions is related to the dose, and is more common per day (rr).
[Contraindications] It is prohibited for those who are allergic to the active substance of this drug or any excipient ingredients .
[Notes] The initial treatment should be carried out by a physician experienced in the treatment of chronic myelogenous leukemia. Approximately - patients taking imatinib mesylate develop severe water retention (pleural effusion, edema, pulmonary edema) edema and ascites), it is therefore recommended to monitor weight regularly. If the weight increases unexpectedly and rapidly during medication, detailed examination should be carried out, and appropriate supportive treatment and treatment measures should be taken if necessary. Water retention can aggravate or lead to heart failure. Currently, there is no Experience with the clinical application of imatinib mesylate in patients with severe heart failure (Grade - according to the New York Heart Association classification). Use this drug with caution in these patients. The dose of imatinib mesylate may be increased in patients with liver failure. Patients with liver damage should use this drug with caution. Long-term clinical data on the safety and effectiveness of this drug are limited. Preclinical studies have shown that imatinib mesylate does not readily pass through the blood-brain barrier. It has not been studied in humans. It is advisable to check the complete blood count every week in the first month of imatinib mesylate treatment, once a week in the first month, and then as needed (such as monthly checks). If severe neutropenia or thrombocytopenia occurs, the dose should be adjusted. Liver function (including transaminases, bilirubin, and alkaline phosphatase) should be checked before starting treatment, and then checked monthly or based on clinical conditions, and the dose should be adjusted if necessary. Effects on the abilities of the driver and machine operator There is no information on possible effects on the abilities of the driver or machine operator.
[Drug use in pregnant and lactating women] Pregnancy: Animal studies have shown that this drug has toxic effects on the reproductive system, but there is currently a lack of data on its use in pregnant women, and the possible toxicity to the fetus is currently unknown. It should not be used during pregnancy unless the possible benefits outweigh the harm to the fetus/infant. If imatinib mesylate is taken during pregnancy, you must be informed of the possible harm to the fetus. Women of childbearing age should be advised to use effective contraception while taking imatinib mesylate. Breastfeeding: In animal experiments, imatinib mesylate and its metabolites were excreted in breast milk in large quantities, but no human studies have been conducted. Women taking imatinib mesylate should not breastfeed.
[Pediatric Medication] In individual samples, the plasma concentration of children can increase by 20%. This data is not enough to be used as a basis for recommending drug dosage for children.
[Drug use in elderly patients] It is known that creatinine clearance can decrease with age, but age has no significant impact on the pharmacokinetics of imatinib mesylate.
【Drug Overdose】There is little experience with overdose, and there are no case reports of overdose. If overdose occurs, the patient should be closely observed and given appropriate supportive care.